Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 2, 2023
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
[ Thu, Nov 02nd 2023
] - WOPRAI
Gena Wang Maintained (SRPT) at Buy with Decreased Target to $141 on, Nov 2nd, 2023
Gena Wang of Barclays, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $193 to $141 on, Nov 2nd, 2023.
Gena has made no other calls on SRPT in the last 4 months.
There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Gena's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Gena
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
- Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $148 on, Tuesday, October 31st, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023
- Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Tuesday, September 26th, 2023
